Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 6, 2011, Pages 1163-1170

  Pautard, B ^a   D'Oiron, R ^b   Li Thiao Te, V ^a   Lavend'Homme, R ^c   Saint Remy, J M ^c   Peerlinck, K ^c   Jacquemin, M ^c  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Factor VIII; Hemophilia A; Inhibitor; T cell

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8 INHIBITOR ANTIBODY; CORTICOSTEROID; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; PROTEIN ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ADOLESCENT; AMINO ACID SUBSTITUTION; ANTIBODY TITER; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; BLEEDING; CD4+ T LYMPHOCYTE; CELL THERAPY; CHILD; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DESENSITIZATION; DISEASE SEVERITY; DRUG HALF LIFE; DRUG MECHANISM; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; PRIORITY JOURNAL; PROPHYLAXIS; REPEAT PROCEDURE; SCHOOL CHILD; SIDE EFFECT; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INTERLEUKINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 79958070755     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04267.x     Document Type: Article

References (29)

1. Brackmann HH, Gormsen J. Massive FVIII infusion in haemophiliac with factor VIII inhibitor, high responder. Lancet. 1977; 2: 933.
2. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 7: 1446-56.
3. Peng B, Ye P, Rawlings DJ, Ochs HD, Miao CH. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood 2009; 114: 4373-82.
4. Miao CH, Harmeling BR, Ziegler SF, Yen BC, Torgerson T, Chen L, Yau RJ, Peng B, Thompson AR, Ochs HD, Rawlings DJ. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. Blood 2009; 114: 4034-44.
5. Finn JD, Ozelo MC, Sabatino DE, Franck HW, Merricks EP, Crudele JM, Zhou S, Kazazian HH, Lillicrap D, Nichols TC, Arruda VR. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 2010; 116: 5842-8.
6. Zhang AH, Skupsky J, Scott DW. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood 2011; 117: 2223-6.
7. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-8.
8. Gilles JG, Grailly SC, De Maeyer M, Jacquemin MG, VanderElst LP, Saint-Remy JM. In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody. Blood 2004; 103: 2617-23.
9. Hausl C, Ahmad RU, Sasgary M, Doering CB, Lollar P, Richter G, Schwarz HP, Turecek PL, Reipert BM. High dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106: 3415-22.
10. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update. Haematologica 2000; 85 (10 Suppl): 48-50.
11. Franchini M, Mengoli C, Lippi G, Targher G, Montagnana M, Salvagno GL, Zaffanello M, Cruciani M. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008; 14: 903-12.
12. Singer ST, Addiego JE, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant Factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
13. Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, Key NS, Conti-Fine BM. Sensitization of CD4+ T cells to coagulation Factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
14. Jacquemin M, Vantomme V, Buhot C, Lavend'homme R, Burny W, Demotte N, Chaux P, Peerlinck K, Vermylen J, Maillere B, van der Bruggen P, Saint-Remy JM. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
15. Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, Gaston JS, Baker MP. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost 2005; 3: 991.
16. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007; 5: 2399-407.
17. Kamaté C, Lenting PJ, van den Berg HM, Mutis T. Depletion of CD4+/CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals. J Thromb Haemost 2007; 5: 611-3.
18. Ragni MV, Bontempo FA, Lewis JH. Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC. Transfusion. 1989; 29: 447-9.
19. Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, Eyster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-9.
20. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990; 63: 1249-56.
21. Rocha B, von Boehmer H. Peripheral selection of the T cell repertoire. Science 1991; 251: 1225-8.
22. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113: 451-63.
23. Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, Lavend'homme R, Johnson KM, Freson K, Scandella D, Saint-Remy JM, Vermylen J. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999; 93: 2267-73.
24. Hu G, Guo D, Key NS, Conti-Fine BM. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 2007; 97: 788-94.
25. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009; 114: 1423-8.
26. Miao CH. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 2010; 3: 469-83.
27. Aznar JA, Jorquera JI, Peiro A, Garcia I. The importance of corticoids added to continued treatment with Factor VIII concentrates in the suppression of inhibitors in haemophilia A. Thromb Haemost 1984; 51: 217-21.
28. Zacharchuk CM, Mercep M, Chakraborti P, Simons SS Jr, Ashwell JD. Programmed T lymphocyte death: cell activation- and steroid-induced pathways are mutually antagonistic. J Immunol 1990; 145: 4037-45.
29. Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.